27 results
8-K
EX-99.2
RETA
Reata Pharmaceuticals Inc
10 May 22
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
6:48am
for implementation Payer mix determined for addressable market Payer engagement initiated in March, communicating FA disease severity and need for treatment Product
8-K
EX-99.2
RETA
Reata Pharmaceuticals Inc
10 May 23
Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial
6:45am
engagement Reviewing supplement as a Prior Approval Supplement (PAS) under an expedited Priority Review Target action date in mid August With Priority
8-K
EX-3.4
RETA
Reata Pharmaceuticals Inc
26 Sep 23
Termination of a Material Definitive Agreement
5:25pm
or engagement or to pledge its credit or to render it liable pecuniarily for any purpose or to any amount.
SECTION 5.02. Deposits. All funds
8-K
EX-3.2
RETA
Reata Pharmaceuticals Inc
26 Sep 23
Termination of a Material Definitive Agreement
5:25pm
have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable pecuniarily for any
8-K
EX-1.1
geqyce
26 Jul 18
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
obtuh6wsak3
10 Oct 19
Entry into a Material Definitive Agreement
6:51am
8-K
EX-1.1
65eleu2reror878toya
14 Nov 19
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-1.1
jzhnm9vi
3 Dec 20
Entry into a Material Definitive Agreement
4:45pm
PREM14A
mab4u5eue e2g
11 Aug 23
Preliminary proxy related to merger
4:38pm
DEFM14A
u8mhm7
22 Aug 23
Proxy related to merger
8:00am